Update on Janus Kinase Antagonists in Inflammatory Bowel Disease

被引：69

作者：

Boland, Brigid S. ^{[1
,2
]}

Sandborn, William J. ^{[1
,2
]}

Chang, John T. ^{[1
,2
]}

机构：

[1] Univ Calif San Diego, Div Gastroenterol, Dept Med, Ctr Inflammatory Bowel Dis, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Digest Dis Res Dev Ctr, La Jolla, CA 92093 USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2014年 / 43卷 / 03期

关键词：

Janus kinase inhibitors; Small-molecule therapy; Tofacitinib; Inflammatory bowel disease; Ulcerative colitis; Crohn disease; B-CELL FUNCTION; CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; INHIBITOR; TOFACITINIB; PLACEBO; JAK2; IMMUNODEFICIENCY; INCB018424; ACTIVATION;

D O I：

10.1016/j.gtc.2014.05.011

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.

引用

页码：603 / +

页数：16

共 51 条

[41] Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation [J].

Shi, Min ;

Lin, Tsung H. ;

Appell, Kenneth C. ;

Berg, Leslie J. .

IMMUNITY, 2008, 28 (06) :763-773

[42] Regulation of JAK-STAT signalling in the immune system [J].

Shuai, K ;

Liu, B .

NATURE REVIEWS IMMUNOLOGY, 2003, 3 (11) :900-911

[43] A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease [J].

Targan, SR ;

Hanauer, SB ;

vanDeventer, SJH ;

Mayer, L ;

Present, DH ;

Braakman, T ;

DeWoody, KL ;

Schaible, TF ;

Rutgeerts, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (15) :1029-1035

[44] Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis [J].

van Vollenhoven, Ronald F. ;

Fleischmann, Roy ;

Cohen, Stanley ;

Lee, Eun Bong ;

Garcia Meijide, Juan A. ;

Wagner, Sylke ;

Forejtova, Sarka ;

Zwillich, Samuel H. ;

Gruben, David ;

Koncz, Tamas ;

Wallenstein, Gene V. ;

Krishnaswami, Sriram ;

Bradley, John D. ;

Wilkinson, Bethanie .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :508-519

[45]

Vanhoutte F, 2014, C ECCO

[46]

Vanhoutte FP, 2012, ANN RHEUM DIS, V71, pS3

[47] Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls [J].

Verstovsek, Srdan ;

Kantarjian, Hagop M. ;

Estrov, Zeev ;

Cortes, Jorge E. ;

Thomas, Deborah A. ;

Kadia, Tapan ;

Pierce, Sherry ;

Jabbour, Elias ;

Borthakur, Gautham ;

Rumi, Elisa ;

Pungolino, Ester ;

Morra, Enrica ;

Caramazza, Domenica ;

Cazzola, Mario ;

Passamonti, Francesco .

BLOOD, 2012, 120 (06) :1202-1209

[48] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. [J].

Verstovsek, Srdan ;

Kantarjian, Hagop ;

Mesa, Ruben A. ;

Pardanani, Animesh D. ;

Cortes-Franco, Jorge ;

Thomas, Deborah A. ;

Estrov, Zeev ;

Fridman, Jordan S. ;

Bradley, Edward C. ;

Erickson-Viitanen, Susan ;

Vaddi, Kris ;

Levy, Richard ;

Tefferi, Ayalew .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12) :1117-1127

[49]

White H, 2000, EUR J IMMUNOL, V30, P732

[50]

Williams W, 2008, ARTHRITIS RHEUM-US, V58, pS431

← 1 2 3 4 5 6 →